Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Dual-Targeting PSMA And FRα Drug Conjugate Advances to U.S. Trial for Prostate Cancer June 18, 2026
- Phase 1 RIALTO Trial: Radiotherapy for Metastatic Prostate Cancer With Incomplete Hormone Response June 18, 2026
- Decipher Genomic Classifier Identifies Patients Who Benefit from Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer June 18, 2026
- CRISPR Advances June 16, 2026

Redefining Prostate Cancer Care: The LIBERTAS Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxTelomir-1: Innovative Molecule Slows Tumor Growth and Reduces Chemotherapy Toxicity
/in Preclinical Research/by MaxPhase I Clinical Trial of AZD2284, AZD2287, and AZD2275
/in Clinical Trial, Metastatic, Phase 1/by MaxBreaking Resistance: A Dual-Pathway Drug Shows Promise for Advanced Prostate Cancer
/in Preclinical Research/by MaxEnzalutamide Boosts PSA Control in High-Risk Prostate Cancer: Insights from the EMBARK Trial
/in Post-hoc, Retrospective studies/by MaxPhase 1/2 trial: Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxAI-Designed ATR Inhibitors Advance to Preclinical Testing
/in Preclinical Research/by MaxFutureChem Launches Phase 3 Trial for Novel PSMA-Targeted Radiopharmaceutical FC705
/in Clinical Trial, Metastatic, Phase 3/by Max